Catalog No.
PAD12602
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
Bevacizumab
Tested applications
ELISA: 1:4000-1:8000
Target
Rabbit polyclonal to Avastin.
Specificity
The product is specific for Bevacizumab. This antibody serves as an excellent positive control for Bevacizumab immunogenicity (ADA) assays.
Concentration
0.5 mg/ml
Purification
Purified by antigen affinity column.
Accession
CAS: 216974-75-3
Applications
ELISA
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles.
Background
Bevacizumab (Avastin) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with colon cancer, lung cancer, glioblastoma, renal-cell carcinoma, and age-related macular degeneration. As angiogenesis inhibitor, Bevacizumab blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Antibodysystem Anti-Bevacizumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Bevacizumab.
Advances in Molecular Imaging of VEGFRs: Innovations in Imaging and Therapeutics., PMID:40508182
The use of Bevacizumab in the treatment of brain arteriovenous malformations: a systematic review., PMID:40504282
Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer., PMID:40501444
Bevacizumab in recurrent epithelial ovarian cancer: real-world experience from a tertiary cancer hospital in India., PMID:40496305
Lenvatinib versus bevacizumab when combined with PD-1/L1 inhibitor and hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma., PMID:40486515
Multimodal nanoparticles co-delivering bevacizumab and dichloroacetate for dual targeting of neoangiogenesis and hyperglycolysis in glioblastoma treatment., PMID:40482922
Efficacy of Hepatic Artery Infusion Chemotherapy with Bevacizumab and Sintilimab in Advanced Hepatocellular Carcinoma: A Case Report., PMID:40481624
Safety and efficacy of systemic chemotherapy plus PD-1 inhibitor in combination with intravenous or intraperitoneal bevacizumab in gastric cancer with peritoneal metastasis., PMID:40481442
Bevacizumab in ovarian cancer therapy: current advances, clinical challenges, and emerging strategies., PMID:40474872
Clinical characteristics and treatment response of treatment requiring retinopathy of prematurity (ROP) in Big Premature Infants in Turkiye: BIG-ROP Study Group Report No 2 (BIG-ROP STUDY)., PMID:40473274
Design and characterization of intravitreal bevacizumab-loaded PLGA nanoparticles: pharmacokinetic and biodistribution impact., PMID:40471504
EFFICACY AND PROGNOSIS OF ANTI-VEGF AGENTS COMBINED WITH PANRETINAL PHOTOCOAGULATION IN DIABETIC RETINOPATHY: A CLINICAL OBSERVATIONAL STUDY., PMID:40466685
Effect of antineoplastic drug therapies on carcinoma and aggressive pituitary tumors: a systematic review and meta-analysis., PMID:40457103
Anti-VEGF Agents Clearance Through the Aqueous Outflow Pathway in a Rat Model., PMID:40455045
Several Common Genetic Variations Associate With Functional or Anatomic Effects of Anti-VEGF Treatment in Conditions With Macular Edema., PMID:40455044
Soft tissue metastasis in colorectal cancer: a case report., PMID:40448204
[Metastatic meningiomas: a case series and literature review]., PMID:40444717
Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers., PMID:40442146
Efficacy of combined therapy with gamma knife radiosurgery and bevacizumab on survival outcomes in patients with recurrent high-grade glioma: a systematic review and meta-analysis., PMID:40439764
Efficacy and Safety of Lenvatinib versus Atezolizumab Plus Bevacizumab in the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis., PMID:40439364
Acetylation-induced degradation of ECHS1 enhances BCAA accumulation and proliferation in KRAS-mutant colorectal cancer., PMID:40437561
Effect of a Biweekly Dosing Schedule on Severe Neutropenia Induced by Trifluridine/Tipiracil in Colorectal Cancer., PMID:40425353
Treatment Options for Alkali Burn-Induced Corneal Neovascularization: A Comparative Analysis of Two Tyrosine Kinase Inhibitors., PMID:40424526
[A Case of Locally Advanced Rectal Cancer in Which Pathological Complete Response Was Achieved with CAPOX and Bevacizumab Chemotherapy]., PMID:40420376
The accelerating effect of sugar on wound healing delayed by bevacizumab: A case report., PMID:40419918
Multi-modality imaging for precise intra-arterial delivery of mRNA, AAVs, and antibodies to the head and neck area in mice., PMID:40418990
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial., PMID:40409323
Efficacy and safety of prophylactic simultaneous intravitreal moxifloxacin injection with standard intravitreal anti-VEGF injection procedure in cases of cystoid macular edema and macular neovascularization., PMID:40405143
Comparison of three loading doses of bevacizumab and ranibizumab for macular edema due to branch retinal vein occlusion., PMID:40405136
Ovarian Cancer Therapy., PMID:40389314
[Age-related macular degeneration - Part 2: therapeutic options for AMD]., PMID:40389215
Biomarker, efficacy and safety analysis of transcatheter arterial chemoembolization combined with atezolizumab and bevacizumab for unresectable hepatocellular carcinoma., PMID:40387956
Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma., PMID:40387836
Evaluation of Baseline Characteristics and Therapeutic Management Strategies in Metastatic Cervical Cancer in Germany: A Multicentric Retrospective Longitudinal Observational Study: A Quality Assurance Initiative of the AGO-Study Group and AGO-OK Uterus., PMID:40386500
Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial., PMID:40379690
Complete remission of a high-risk, locally advanced cervical cancer with para-aortic lymph node metastases treated with first-line tislelizumab plus bevacizumab combined with chemotherapy followed by radiotherapy with maintenance therapy: a case report., PMID:40375998
[A Case of Rectal Cancer with Lateral Lymph Node, Liver and Lung Metastases after Surgery, Successfully Undergoing Radical Resection with Multidisciplinary Treatment]., PMID:40360412
The BEV1L study: Do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?, PMID:40351123
[Thyrotoxicosis induced by immune checkpoint inhibitor therapy for unresectable hepatocellular carcinoma:a case report]., PMID:40350315
Optimal bevacizumab treatment strategy in advanced ovarian cancer: A review., PMID:40349571
Predicting the efficacy of bevacizumab on peritumoral edema based on imaging features and machine learning., PMID:40341749
Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE study., PMID:40341031
Contributing factors to short-term intraocular pressure elevation following intravitreal anti-VEGF injections., PMID:40335957
Endophthalmitis following intravitreal injections at a tertiary center: real-life data on incidence, risk factors, management strategies, and visual outcomes., PMID:40335933
Genome-wide DNA methylation status as a biomarker for clinical outcomes of first-line treatment in patients with RAS wild-type metastatic colorectal cancer: JACCRO CC-13AR., PMID:40334314
Visual fields after anti-vascular endothelial growth factor therapy for retinopathy of prematurity., PMID:40333931
Comparing visual outcomes of nAMD treatment during and after the COVID-19 restrictions period., PMID:40333806
Predictive factors for adherence to intravitreal anti-vascular endothelial growth factor therapy in Palestinian patients with diabetic retinopathy, retinal vein occlusion, and age-related macular degeneration: a retrospective cohort study., PMID:40329243
Prognosis and Therapy of Ovarian Cancer, Part 2: the shifting landscape of medical treatment in ovarian cancer., PMID:40324343
Anterior segment changes in nonproliferative diabetic patient with macular edema treated by intravitreous bevacizumab injection., PMID:40324240
For research use only. Not for human or drug use.
